Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 16/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | XBP1 | P17861 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6839121 | 1.00 | ABCB1 (0.47) | ABCB1NPC1XBP1HTTRAB9A | |
| SCHEMBL6839082 | 0.91 | ABCB1 (0.49) | ABCB1NPC1XBP1HTTRAB9A | |
| SCHEMBL6839079 | 0.91 | ABCB1 (0.49) | ABCB1NPC1XBP1HTTRAB9A | |
| SCHEMBL21694355 | 0.91 | ABCB1 (0.49) | ABCB1NPC1XBP1HTTRAB9A | |
| SCHEMBL13973622 | 0.86 | ABCB1 (0.48) | ABCB1NPC1XBP1HTTRAB9A | |
| SCHEMBL16027312 | 0.86 | ABCB1 (0.48) | ABCB1NPC1XBP1HTTRAB9A | |
| SCHEMBL16027313 | 0.86 | ABCB1 (0.48) | ABCB1NPC1XBP1HTTRAB9A | |
| SCHEMBL21694335 | 0.80 | ABCB1 (0.36) | ABCB1CYP2D6THRBHSD17B10 | |
| SCHEMBL13973623 | 0.74 | ABCB1 (0.44) | ABCB1NPC1XBP1HTTRAB9A | |
| SCHEMBL22799862 | 0.74 | METAP2 (0.34) | METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229840-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | ISIS PHARMACEUTICALS, INC. | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229840-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ABCB1 592/4885NPC1 358/4885XBP1 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.